Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide

Martin Gore; R Powles; A. Lakhani; Sarah Milan; Jennifer Maitland; Glen Goss; A Nandi; Timothy Perren; Garry Forgeson; Jennifer Treleaven; A. Zuiable; Fulvio Porta

doi:10.1007/bf00435839

JOURNAL ARTICLE

Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide

Martin Gore R Powles A. Lakhani Sarah Milan Jennifer Maitland Glen Goss A Nandi Timothy Perren Garry Forgeson Jennifer Treleaven A. Zuiable Fulvio Porta

Year: 1989 Journal: Cancer Chemotherapy and Pharmacology Vol: 23 (6)Pages: 373-376 Publisher: Springer Science+Business Media

DOI: 10.1007/bf00435839

Get Full-Text PDF Get Analytical Report

Keywords:

Etoposide Medicine Internal medicine Refractory (planetary science) Anthracycline Cytarabine Complete remission Gastroenterology Leukemia Surgery Chemotherapy Cancer

Metrics

Cited By

3.24

FWCI (Field Weighted Citation Impact)

Refs

0.92

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Citation History

Topics

Acute Myeloid Leukemia Research

Health Sciences → Medicine → Hematology

Acute Lymphoblastic Leukemia research

Health Sciences → Medicine → Public Health, Environmental and Occupational Health

Lung Cancer Research Studies

Health Sciences → Medicine → Oncology

Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide

Metrics

Citation History

Topics

Related Documents

Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia

Low-Dose Cytosine Arabinoside in the Treatment of Relapsed and Refractory Acute Non-Lymphocytic Leukaemia

High-Dose Cytosine Arabinoside and Etoposide in the Treatment of Relapsed or Refractory Adult Leukemia

Experience with Intermediate and High Dose Cytosine Arabinoside in Refractory Acute Leukaemia

High Dose Cytosine Arabinoside in the Management of Refractory Acute Leukaemia